ADCC Expression Cell Line
Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology, November 2021 Issue
Volume 45
Issue 11
Pages: 12
The ADCC+ Cell Line is designed for rapid identification of clones expressing high levels of recombinant therapeutic proteins.
The ADCC+ Cell Line
PerkinElmer’s antibody-dependent cellular cytotoxicity (ADCC)+ Cell Line is an expression cell line for the company’s Horizon Discovery CHOSOURCE platform, which is designed for rapid identification of clones expressing high levels of recombinant therapeutic proteins.
The ADCC+ cell line eliminates the fucose gene to increase ADCC activity with the intent of improving the potency and efficacy of therapeutic antibodies and fusion protein biotherapeutics. At the same time, it aims to reduce dosage requirements and side effects for patients.
Articles in this issue
The Earlier the Better for Formulation Strategies
Practical SPC Rules in the Real World of an Ongoing Process Verification Plan: Part 2. Practical SPC Rules to Apply on Pharmaceutical Process Data
Taking an Alternative Approach to Drug Delivery
Computational Fluid Dynamics in Upstream Biopharma Manufacturing Processes
GMP/GDP Inspections: Challenges and Opportunities Revealed by the COVID-19 Pandemic
Visual Inspection: Seeing Room for Improvement?
Detecting and Determining Quantitation Limits for Impurities
Labeling Efficiently
Meeting Supply and Training Challenges
Pandemic Alters FDA Inspections and Quality Oversight
Lipids for Self-Emulsifying Drug Delivery Systems
Great Expectations for Excipients
Can We Agree on Conferences?
Making a Difference in European Bio/Pharma
The Remote Audit–A Tongue-in-Cheek Memo
Recent Videos
